

Amit Mahipal

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/2927439/publications.pdf](https://exaly.com/author-pdf/2927439/publications.pdf)

Version: 2024-02-01

168
papers

4,857
citations

132226

32
h-index

119536

62
g-index

190
all docs

190
docs citations

190
times ranked

10414
citing authors

#	ARTICLE	IF	CITATIONS
1	Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer. <i>Current Oncology</i> , 2024, 31, 366-382.	2.3	0
2	Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. <i>JCO Precision Oncology</i> , 2024, , .	3.2	1
3	HER2-directed therapy following ctDNA-identified ERBB2 amplification in patients with advanced gastroesophageal cancer: exploration of real-world outcomes. <i>ESMO Gastrointestinal Oncology</i> , 2024, 4, 100056.	0.0	0
4	Frequency of Common and Uncommon BRAF Alterations among Colorectal and Non-Colorectal Gastrointestinal Malignancies. <i>Cancers</i> , 2024, 16, 1823.	3.8	0
5	Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2024, 16, 1861.	3.8	0
6	Outcome of Patients with Locally Advanced Rectal Cancer Pursuing Non-Surgical Strategy in National Cancer Database. <i>Cancers</i> , 2024, 16, 2194.	3.8	0
7	Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer. <i>Cancers</i> , 2024, 16, 2407.	3.8	0
8	Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer. <i>Pharmacogenomics</i> , 2023, 24, 1-4.	1.4	0
9	A glimpse into the future of esophageal carcinoma in the United States: predicting the future incidence until 2040 based on the current epidemiological data. <i>Journal of Gastrointestinal Oncology</i> , 2023, 14, 1-10.	1.4	3
10	Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020. <i>Oncologist</i> , 2023, 28, 510-519.	4.1	6
11	Circulating Tumor DNA-Guided Recurrence Risk Assessment in Esophageal and Gastric Cancer: Assay Holds the Key. <i>JCO Precision Oncology</i> , 2023, , .	3.2	0
12	Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. <i>JCO Precision Oncology</i> , 2023, , .	3.2	5
13	Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection. <i>European Journal of Surgical Oncology</i> , 2023, 49, 106994.	1.0	2
14	Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. <i>Hpb</i> , 2023, 25, 1502-1512.	0.3	0
15	Differences in the surgical management of early-stage hepatocellular carcinoma at minority versus non-minority-serving hospitals. <i>Surgery</i> , 2023, 174, 1201-1207.	2.0	0
16	<i>Ganoderma adspersum</i> (Schulzer) Donk; <i>Ganoderma applanatum</i> (Pers.) Pat.; <i>Ganoderma lucidum</i> (Curtis) P. Karst.; <i>Ganoderma resinaceum</i> Boud. - GANODERMATAACEAE. <i>Ethnobiology</i> , 2023, , 1135-1169.	0.0	3
17	Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience. <i>JCO Precision Oncology</i> , 2023, , .	3.2	6
18	Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review. <i>JCO Precision Oncology</i> , 2023, , .	3.2	7

#	ARTICLE	IF	CITATIONS
19	Conceptualization and Evaluation of Asiabrood Watershed Health, Chalus Township,. , 2023, 14, 15-25.		1
20	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. Investigational New Drugs, 2022, 40, 134-141.	2.7	22
21	Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1579-1591.	2.0	36
22	PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Gaâ€PSMAâ€11 PET Using Cyclotronâ€Produced 68Ga. Hepatology Communications, 2022, 6, 1172-1185.	4.4	17
23	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. Digestive Diseases and Sciences, 2022, 67, 3797-3805.	2.4	5
24	Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opinion on Therapeutic Targets, 2022, 26, 79-92.	3.5	5
25	Analysis of Registered Clinical Trials in Surgical Oncology, 2008-2020. JAMA Network Open, 2022, 5, e2145511.	6.0	8
26	Isocitrate Dehydrogenaseâ€Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. JCO Precision Oncology, 2022, 6, e2100156.	3.2	12
27	Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 85-98.	3.4	12
28	Reply to F. Nichetti et al. JCO Precision Oncology, 2022, 6, e2200131.	3.2	0
29	Economic Cost and Sustainability of Oral Therapies in Precision Oncology. JCO Oncology Practice, 2022, 18, e1247-e1254.	2.8	7
30	Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers, 2022, 14, 2588.	3.8	11
31	First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines, 2022, 10, 1304.	3.3	10
32	Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)â€Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC). Cancers, 2022, 14, 3078.	3.8	12
33	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precision Oncology, 2022, , .	3.2	5
34	Analysis of Registered Clinical Trials in Gastroenterology, 2007-2019. JAMA Network Open, 2022, 5, e2221770.	6.0	1
35	Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers. JCI Insight, 2022, 7, .	5.0	19
36	Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma. Cancers, 2022, 14, 5173.	3.8	7

#	ARTICLE	IF	CITATIONS
37	Systemic therapy for advanced hepatocellular carcinoma: targeted therapies. Chinese Clinical Oncology, 2021, 10, 10-10.	1.3	11
38	Metastatic Colon Cancer Presenting With Immune-mediated Necrotizing Myopathy. Clinical Colorectal Cancer, 2021, 20, e71-e73.	2.4	1
39	Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry Study. Practical Radiation Oncology, 2021, 11, e63-e69.	2.1	5
40	Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Annals of Surgery, 2021, 273, 341-349.	4.5	294
41	Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy. Journal of Gastrointestinal Oncology, 2021, 12, 2275-2286.	1.4	4
42	Enhanced selectivity and stability towards CO ₂ reduction of sub-5 nm Au NPs derived from supramolecular assembly. Chemical Communications, 2021, 57, 2491-2494.	4.2	6
43	Research Progress of Biliary Tract Cancers. Cancers, 2021, 13, 919.	3.8	0
44	Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1779-1785.	3.1	24
45	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Investigational New Drugs, 2021, 39, 1072-1080.	2.7	5
46	Aspirin and Statin Use and the Risk of Gallbladder Cancer. Cancers, 2021, 13, 1186.	3.8	3
47	Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?. Expert Opinion on Investigational Drugs, 2021, 30, 463-477.	4.0	20
48	A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. Cureus, 2021, 13, e14640.	0.5	4
49	An Empirical Analysis of the Service Efficiency of Basic Public Education Based on the BCC-DEA Model of Neural Network Computing Principles. Journal of Physics: Conference Series, 2021, 1865, 042131.	0.4	4
50	In Vivo Evaluation of Dendropanax morbifera Leaf Extract for Anti-Obesity and Cholesterol-Lowering Activity in Mice. Nutrients, 2021, 13, 1424.	4.2	3
51	Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9. Frontiers in Oncology, 2021, 11, 651119.	2.9	7
52	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. Cancers, 2021, 13, 2968.	3.8	80
53	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precision Oncology, 2021, 5, 1228-1240.	3.2	4
54	TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. , 2021, 224, 107823.		10

#	ARTICLE	IF	CITATIONS
55	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	6.4	26
56	Osteoclast-Like Giant Cell Tumors of the Pancreas. <i>Pancreas</i> , 2021, 50, 952-956.	1.1	2
57	Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5145-5160.	2.1	14
58	Shorter Treatment-Na ⁺ Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 210-216.	1.9	4
59	The Sustainability of Price Dynamics in Precision Hematology. <i>Blood</i> , 2021, 138, 114-114.	1.4	0
60	Comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	1.2	0
61	Knowledge and Attitudes for the Management of Behavioral Variant of Frontotemporal Dementia. <i>Frontiers in Neurology</i> , 2021, 12, 786448.	2.5	3
62	Second-line therapies in advanced biliary tract cancers. <i>Lancet Oncology</i> , The, 2020, 21, e29-e41.	10.8	80
63	Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 1338-1348.	7.2	37
64	Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. <i>Oncologist</i> , 2020, 25, 380-e763.	4.1	10
65	The Puncture and Water Resistance of Polyurethane- Impregnated Fabrics after UV Weathering. <i>Polymers</i> , 2020, 12, 15.	4.6	19
66	The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review. <i>Cancers</i> , 2020, 12, 2808.	3.8	37
67	A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. <i>Oncologist</i> , 2020, 25, e1893-e1899.	4.1	17
68	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	7.3	144
69	Prevention and treatment of FGFR inhibitor-associated toxicities. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103091.	4.5	39
70	Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e1681-e1690.	4.1	6
71	Prevention of Mother-to-Child HIV Transmission Service Utilization among Pregnant Women in Northeast Ethiopia: A Cross-Sectional Survey. <i>Scientifica</i> , 2020, 2020, 1-7.	1.7	4
72	Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm. <i>Cancers</i> , 2020, 12, 2039.	3.8	55

#	ARTICLE	IF	CITATIONS
73	Adaptive grayscale image coding scheme based on dynamic multi-grouping absolute moment block truncation coding. Multimedia Tools and Applications, 2020, 79, 28189-28205.	4.2	10
74	Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 586-590.	1.3	5
75	Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells. Journal of Hepatology, 2020, 73, S122.	3.9	5
76	Updated data from an ongoing study with ADP-A2AFP spear T-cells. Journal of Hepatology, 2020, 73, S910-S911.	3.9	1
77	The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Review of Gastroenterology and Hepatology, 2020, 14, 619-629.	3.0	7
78	The future of adjuvant therapy in ampullary cancer: should we offer it to our patients?. Hepatobiliary Surgery and Nutrition, 2020, 9, 368-370.	1.2	2
79	Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer. Hpb, 2020, 22, 1490-1495.	0.3	15
80	Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. European Journal of Surgical Oncology, 2020, 46, 789-795.	1.0	16
81	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. JAMA Oncology, 2020, 6, 888.	7.3	322
82	Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 3557-3564.	7.2	4
83	Survival and prognostic factors in patients with rectal squamous cell carcinoma. European Journal of Surgical Oncology, 2020, 46, 1111-1117.	1.0	13
84	Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World Journal of Gastrointestinal Oncology, 2020, 12, 808-832.	2.0	68
85	Collateral damage of COVID-19 pandemic on oncology clinical trials. Chinese Clinical Oncology, 2020, 9, 80-80.	1.3	2
86	Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer. Journal of Gastrointestinal Oncology, 2020, 11, 1408-1420.	1.4	11
87	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2020, , 731-757.		1
88	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 554-561.	1.4	35
89	Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?. Cancers, 2019, 11, 1078.	3.8	37
90	FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Cancer Treatment Reviews, 2019, 78, 1-7.	8.0	59

#	ARTICLE	IF	CITATIONS
91	A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. <i>PLoS ONE</i> , 2019, 14, e0221994.	2.5	24
92	Survival and prognostic factors in patients with pancreatic squamous cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1700-1705.	1.0	11
93	Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 171-178.	1.4	20
94	Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 218-225.	2.4	14
95	First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1211-1222.	4.4	22
96	Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1432-1438.	1.0	73
97	Microglial LOX-1/MAPKs/NF- κ B positive loop promotes the vicious cycle of neuroinflammation and neural injury. <i>International Immunopharmacology</i> , 2019, 70, 187-200.	3.8	18
98	Solid Pseudopapillary Neoplasms of the Pancreas. <i>Pancreas</i> , 2019, 48, e21-e22.	1.1	5
99	<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10463-10476.	2.0	62
100	<p>Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10335-10342.	2.1	20
101	Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.2	45
102	Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2019, 21, 379-386.	0.3	12
103	Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2019, 37, 473-481.	2.7	11
104	Multidisciplinary Management of Liver, Pancreatic, and Gastric Malignancies in Older Adults. , 2019, , 1-28.		0
105	Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. <i>European Journal of Surgical Oncology</i> , 2018, 44, 677-683.	1.0	45
106	Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 133-139.	1.3	5
107	Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 236-241.	1.3	17
108	Corporate social responsibility and multinational enterprise identity: insights from a mining company's attempt to localise in Ghana. <i>Social Identities</i> , 2018, 24, 604-623.	0.6	36

#	ARTICLE	IF	CITATIONS
109	Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opinion on Therapeutic Targets, 2018, 22, 9-17.	3.5	13
110	Novel Immunotherapy Strategies for Hepatobiliary Cancers. Immunotherapy, 2018, 10, 1077-1091.	2.0	6
111	Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas. Pancreas, 2018, 47, 1003-1007.	1.1	24
112	Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers, 2018, 10, 24.	3.8	66
113	Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 709-720.	4.0	43
114	Staging and Prognostic Implications. , 2018, , 109-118.		0
115	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma. Clinical Cancer Research, 2017, 23, 5339-5348.	7.2	154
116	Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2017, 35, 1304-1311.	15.4	89
117	Role of Biologics in First-Line Treatment of Colorectal Cancer. Journal of Oncology Practice, 2016, 12, 1219-1228.	3.0	35
118	Malignant transformation of biliary adenofibroma: a rare biliary cystic tumor. Journal of Gastrointestinal Oncology, 2016, 6, E107-E112.	1.4	16
119	Wave reaction of a dipole in a circulatory double-layer flow of finite depth. Fluid Dynamics, 2016, 51, 214-223.	1.0	3
120	Importins and exportins as therapeutic targets in cancer. , 2016, 164, 135-143.		120
121	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Journal of Clinical Oncology, 2016, 34, 3838-3845.	15.4	745
122	Pharmacokinetics and safety of vitamin E Î-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemotherapy and Pharmacology, 2016, 78, 157-165.	2.4	38
123	Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. Journal of Oncology Pharmacy Practice, 2016, 22, 552-555.	1.0	11
124	Evaluating the kinetics of the esterification of oleic acid with homo and heterogeneous catalysts using in-line real-time infrared spectroscopy and partial least squares calibration. Journal of Molecular Catalysis B: Enzymatic, 2016, 123, 41-46.	1.7	10
125	First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2016, 34, 4142-4150.	15.4	196
126	Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PLoS ONE, 2016, 11, e0151632.	2.5	33

#	ARTICLE	IF	CITATIONS
127	Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1281-1292.	10.4	12
128	PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Clinical Nuclear Medicine, 2015, 40, e501-e505.	1.5	31
129	Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody [®] targeting the DR5 receptor. Cancer Chemotherapy and Pharmacology, 2015, 75, 887-895.	2.4	118
130	A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2015, 46, 284-290.	1.4	14
131	Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Molecular Cancer Therapeutics, 2015, 14, 1570-1581.	3.7	55
132	A new time-domain corner diffraction coefficient for metallic and dielectric objects for UWB signals. Microwave and Optical Technology Letters, 2015, 57, 1760-1765.	1.5	2
133	Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. Investigational New Drugs, 2015, 33, 1093-1099.	2.7	6
134	Phase I study of combination of pasireotide LAR + Gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 481-487.	2.4	11
135	Management of borderline resectable pancreatic cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 241.	2.0	27
136	Risks and Benefits of Phase 1 Clinical Trial Participation. Cancer Control, 2014, 21, 193-199.	1.9	18
137	Epidermal Growth Factor Receptor Inhibitors: Coming of Age. Cancer Control, 2014, 21, 74-79.	1.9	57
138	Clinical Trials and Drug Development. Cancer Control, 2014, 21, 188-189.	1.9	1
139	Participation of the Elderly Population in Clinical Trials: Barriers and Solutions. Cancer Control, 2014, 21, 209-214.	1.9	122
140	Selinexor. Exportin-1 (XPO1) inhibitor, Oncolytic. Drugs of the Future, 2014, 39, 685.	0.1	1
141	Viral Vector Vaccines To Treat Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 398-405.	0.5	2
142	The effect of carbon nanotubes on biomineralization and solubility of calcium hydroxyapatite Ca ₁₀ (PO ₄) ₆ (OH) ₂ . Protection of Metals and Physical Chemistry of Surfaces, 2013, 49, 80-86.	1.1	6
143	Role of Systemic Chemotherapy in Urothelial Urinary Bladder Cancer. Cancer Control, 2013, 20, 200-210.	1.9	22
144	A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Research, 2012, 22, 440-446.	1.2	76

#	ARTICLE	IF	CITATIONS
145	HHV-8 Associated Multicentric Castleman's Disease in HIV-Negative Patient: A Novel Therapy for an Orphan Disease. <i>Oncologist</i> , 2012, 17, 145-146.	4.1	10
146	Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. <i>Medical Oncology</i> , 2012, 29, 134-139.	2.7	18
147	Microparticle enlargement is a key point of vascular injury caused by decompression stress. <i>FASEB Journal</i> , 2012, 26, 1082.9.	0.5	0
148	Observed and simulated precursors of stratospheric polar vortex anomalies in the Northern Hemisphere. <i>Climate Dynamics</i> , 2011, 37, 1443-1456.	3.8	64
149	Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1039-1045.	4.4	23
150	The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia. <i>Current Oncology Reports</i> , 2010, 12, 352-354.	4.1	0
151	Nonanthracycline Induction Chemotherapy (T-FLAG) for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 4356-4356.	1.4	0
152	HHV8 Associated Multicentric Castleman's Disease In a HIV Negative Patient Responding to Treatment with Bortezomib and Gancyclovir- A Novel Therapy for An Orphan Disease. <i>Blood</i> , 2010, 116, 4897-4897.	1.4	0
153	Temperature dependent reflection anisotropy spectroscopy investigations of vanadyl phthalocyanine films. <i>Physica Status Solidi C: Current Topics in Solid State Physics</i> , 2008, 5, 1202-1205.	0.8	0
154	A live trap model for subterranean mole rats. <i>Mammalia</i> , 2007, 71, .	0.7	2
155	Acquired hemophilia in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 1026-1028.	1.4	12
156	A case of acquired hemophilia associated with bullous pemphigoid. <i>American Journal of Hematology</i> , 2007, 82, 502-502.	4.3	12
157	Fatal Pulmonary Toxicity After a Single Dose of Cyclophosphamide. <i>Pharmacotherapy</i> , 2007, 27, 616-618.	2.7	17
158	Nonsteroidal Anti-inflammatory Drugs and Subsite-Specific Colorectal Cancer Incidence in the Iowa Women's Health Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1785-1790.	1.9	61
159	Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. <i>Cancer</i> , 2005, 104, 1834-1839.	4.1	43
160	A hybrid replication technique for the analysis of precipitate-boundary interactions in Ni-based superalloys. <i>Journal of Materials Science</i> , 2005, 40, 3403-3407.	3.7	8
161	EDV-technische Umsetzung des Meldewesens. <i>Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz</i> , 2000, 43, 880-881.	1.8	2
162	Direct observation of Myosin-ADP-Fluorometal complexes using quick-freeze deep etch electron microscopy and interaction with fluorescent probe prodan.. <i>Seibutsu Butsuri</i> , 1999, 39, S187.	0.1	0

#	ARTICLE	IF	CITATIONS
163	Expression of Growth-Related Genes in Human Fetal Kidney. , 1991, , 1298-1303.		0
164	Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist, 0, , .	4.1	0
165	FOxTROT Study Results: Some Burning Questions Need Answers. Journal of Clinical Oncology, 0, , .	15.4	0
166	Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date. OncoTargets and Therapy, 0, Volume 17, 383-394.	2.1	0
167	Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study. Oncologist, 0, , .	4.1	0
168	Devimistat (CPI-613) With Modified Fluorouracil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. Journal of Clinical Oncology, 0, , .	15.4	0